Marplan: profile and news

FDA approves first patch to treat depression Feb 28, 2006
Other MAOI drugs on the market include Pfizer Inc.'s Nardil, GlaxoSmithKline Plc's Parnate and Oxford Pharmaceutical Services Inc.'s Marplan, as well as ... - Reuters.uk,

FDA Warning: Using Paxil Raises Birth Defects Risk Dec 8, 2005
MAOI drugs include Nardil (phenelzine sulfate), Parnate (tranylcypromine sulfate), Marplan (isocarboxazid), and other brands. ... - Food Consumer,

74.1 million mobile customers at end-June Aug 16, 2005
Figures from market research institute Marplan shows that the number of mobile phone customers in Germany reached 74.1 million at end-June, reports Handelsblatt ... - Telecom Paper (subscription),

Mobile subscribers in Germany hit 74.1 million, as Nigeria attains ... Sep 4, 2005
In addition to this, a survey conducted by the market research group, Marplan revealed that 30 per cent of Germans do not own a mobile phone showing that a ... - Vanguard,

Germany cellphone's booming Aug 15, 2005
June. However, a survey, drawn up by the market research group, Marplan, found that 30% of Germans did not own a cellphone. The ... - Finance24,

Telekom drops bid for mobile phone group 02 Aug 16, 2005
However, a survey, drawn up by the market research group, Marplan, found that 30 per cent of Germans did not own a mobile phone. ... - Expatica,

Look in the small print for the truth about polls Peter Preston Apr 2, 2005
In the elections of long ago, Professor Peter Cole, then news editor of the Guardian , used to herald the arrival of yet another Marplan opinion poll as 'The ... - Guardian,

FDA Safety Labeling Changes: CombiPatch, Antidepressants Mar 23, 2005
Squibb company); chlordiazepoxide plus amitriptyline HCl tablets (Limbitrol, made by Valeant Pharmaceuticals, Inc.); isocarboxazid tablets (Marplan, made by ... - Medscape (subscription)

Other information

Indication
Isocarboxazid is used to treat depression, especially when the patient is excitable or suffering from phobias (fears).

Pharmacology
Isocarboxazid is a non-selective hydrazine monoamine oxidase (MAO) inhibitor used to treat depression. In vivo and in vitro studies demonstrated inhibition of MAO in the brain, heart, and liver. Depression is a complicated disease that is not fully understood. It is thought that depression may be linked to an imbalance of chemicals within the brain. When depression occurs, there may be a decrease in the amount of chemicals released from nerve cells in the brain. These chemicals are called monoamines. Monoamines are broken down by a chemical called monoamine oxidase. Isocarboxazid prevents monoamine oxidase from breaking down the monoamines. This results in an increased amount of active monoamines in the brain. By increasing the amount of monoamines in the brain, the imbalance of chemicals thought to be caused by depression is altered. This helps relieve the symptoms of depression.

Mechanism Of Action
Isocarboxazid works by irreversibly blocking the action of a chemical substance known as monoamine oxidase (MAO) in the nervous system. MAO subtypes A and B are involved in the metabolism of serotonin and catecholamine neurotransmitters such as epinephrine, norepinephrine, and dopamine. Isocarboxazid, as a nonselective MAO inhibitor, binds irreversibly to monoamine oxidase–A (MAO-A) and monoamine oxidase–B (MAO-B). The reduced MAO activity results in an increased concentration of these neurotransmitters in storage sites throughout the central nervous system (CNS) and sympathetic nervous system. This increased availability of one or more monoamines is the basis for the antidepressant activity of MAO inhibitors.

Drug Category
Antidepressants; ATC:N06AF01

Brand Names/Synonyms
BMIH; Benazide; CHEMBANK3383; Enerzer; Isocarbonazid; Isocarbossazide; Isocarbossazide [Dcit]; Isocarboxazid; Isocarboxazid [Ban:Inn]; Isocarboxazida [Inn-Spanish]; Isocarboxazide; Isocarboxazide [Inn-French]; Isocarboxazidum [Inn-Latin]; Isocarboxyzid; Maraplan; Marplan; Marplon

Dosage Forms
TABLET

Absorption
Well absorbed from the gastrointestinal tract.

Interactions
Interactions for Isocarboxazid: Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories). In a single study, rats given high intraperitoneal doses of an MAO inhibitor plus disulfiram experienced severe toxicity, including convulsions and death. Concomitant use of Isocarboxazid and other psychotropic agents is generally not recommended because of possible potentiating effects. This is especially true in patients who may subject themselves to an overdosage of drugs. If combination therapy is needed, careful consideration should be given to the pharmacology of all agents to be used. The monoamine oxidase inhibitory effects of Isocarboxazid may persist for a substantial period after discontinuation of the drug, and this should be borne in mind when another drug is prescribed following Isocarboxazid. To avoid potentiation, the physician wishing to terminate treatment with Isocarboxazid and begin therapy with another agent should allow for an interval of 10 days.

Chemical IUPAC Name
N-benzylamino-5-methyl-oxazole-3-carboxamide

Chemical Formula
C12H13N3O2

Half Life
Not Available

Drug Type
Approved Drug

# Accession No
APRD00701

CAS Registry Number
59-63-2